WBA stock $11.98 on NASDAQ 20 Feb 2026 after 452,081,061.00 volume: analyst outlook

WBA stock closed at $11.98 on NASDAQ on 20 Feb 2026 after an outsized 452,081,061.00 share session, making it one of the most active names today. Traders pushed volume to roughly 26.69 times the average, on the back of mixed fundamentals and fresh analyst attention. We examine why Walgreens Boots Alliance, Inc. (WBA) moved, what the key ratios show, and how the latest market signals shape a short- and medium-term outlook for investors in the United States, quoted in USD.

WBA stock price action and market activity

Walgreens Boots Alliance, Inc. (WBA) finished the session at $11.98 after opening at $11.98 and a previous close of $11.92. Volume spiked to 452,081,061.00, versus an average volume of 16,940,296.00, producing a relative volume of 26.69. The 52-week range is $8.08 low and $13.25 high, while 50-day and 200-day averages sit at $11.66 and $10.81 respectively. The session suggests active repositioning by institutions and retail traders ahead of next earnings and analyst updates.

WBA stock fundamentals and valuation

Walgreens reports trailing EPS of -7.29 and a negative PE of -1.64, reflecting recent losses and one-off items. Market capitalization stands at 10,369,421,068.00 USD. Key valuation metrics include price-to-sales 0.07 and price-to-book 1.44. Balance-sheet stress shows debt-to-equity of 4.04 and current ratio 0.60, indicating leverage pressure. Free cash flow per share is 0.67, with a free cash flow yield near 5.59%, underscoring operating cash conversion but limited margin support for dividends today.

WBA stock technicals and momentum indicators

Technical indicators show short-term strength: RSI at 100.00 and ADX at 50.00 indicate a strong trend on heavy volume. The 50-day at $11.66 and 200-day at $10.81 position price above both averages. Keltner Channels read Upper 12.26, Middle 11.93, Lower 11.60, signaling compressed volatility within a strong directional move. Traders should note an ATR of 0.16, meaning daily swings remain modest in dollar terms despite high turnover.

Meyka AI rates WBA with a score out of 100 and forecast

Meyka AI rates WBA with a score out of 100: 61.90 (Grade B) and suggests HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a 12-month base price target of $9.50, implying a downside of -20.70% from the current $11.98. Forecasts are model-based projections and not guarantees. The grade and forecast are part of our AI-powered market analysis platform and are informational only.

Analyst consensus, recent price targets and news impact

Recent coverage shows mixed analyst views and a MarketBeat price target at $9.00 for WBA stock, which aligns with downside pressure noted in our forecast source. Media coverage of index changes and strategic reviews continues to influence sentiment; Walgreens’ role in the Dow and comparative underperformance is noted by investors source. Upgrade/downgrade tallies show one Hold and two Sell ratings in the available consensus data.

WBA stock risks and catalysts to watch

Key risks include high leverage (debt-to-equity 4.04), negative EPS trend, and margin pressure from healthcare reimbursement changes. Catalysts that could lift WBA stock include better-than-expected cost reductions, improved pharmacy margins, divestiture clarity, or a return to positive EPS growth. Monitor short interest and corporate updates ahead of the next earnings date set for 25 Jun 2025. Sector moves in Healthcare and retail pharmacy consolidation remain important for relative performance.

Final Thoughts

WBA stock traded as one of the most active names today, closing at $11.98 on NASDAQ with 452,081,061.00 shares changing hands. Fundamentals show stress—EPS -7.29, PE -1.64, high leverage—while cash flow metrics and price-to-book provide limited support. Meyka AI’s grade (B, 61.90/100) reflects mixed signals: steady revenues but weak profitability and balance sheet strain. Our model projects $9.50, a -20.70% implied downside from today’s price, while a constructive scenario to $13.50 would imply a 12.69% upside. Investors should weigh short-term momentum against structural risks in the Healthcare retail sector and track upcoming earnings and corporate actions. These views are data-driven analysis and not investment advice; use them to frame position sizing and risk management in USD on the NASDAQ market.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.